TLB001
/ TianLi Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 26, 2025
TLB-001 safety and tolerability study
(ANZCTR)
- P1 | N=64 | Completed | Sponsor: Tianli Biotech Pty Ltd | Recruiting ➔ Completed
Trial completion • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
September 06, 2024
TLB-001 safety and tolerability study
(ANZCTR)
- P1 | N=64 | Recruiting | Sponsor: Tianli Biotech Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2024
Enrollment open • Trial initiation date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
July 05, 2024
TLB-001 safety and tolerability study
(ANZCTR)
- P1 | N=64 | Not yet recruiting | Sponsor: Tianli Biotech Pty Ltd
New P1 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1